Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,227 recruiting studies in this area right now.
By phase
- Not applicable3,140
- Phase 21,067
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4236
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis342
- Multiple Myeloma333
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes132
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona140
- New York122
- Massachusetts119
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,227 total
- NCT07720765Recruiting
Using eye scans to study brain diseases
This trial uses a type of eye scan (OCT) to look at the retina in people with brain conditions like multiple sclerosis, Alzheimer's, Parkinson's, or migraines. It aims to see if these scans can help doctors learn more about the disease and monitor it over time.
Milan, MilanoAges 18 years+ - NCT07239947RecruitingPhase 1
Testing BBT001 for healthy volunteers and people with eczema
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
Hefei, AnhuiAges 18–65 - NCT06371417RecruitingPhase 1
Testing RAY121 for several immune diseases (RAINBOW trial)
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
Orange, CaliforniaAges 18–85 - NCT07717905RecruitingPhase 1/Phase 2
Testing BBT001 for chronic hives
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
Wuhu, AnhuiAges 18–75 - NCT07721142RecruitingPhase 4
Chinese medicine and Western medicine for hard-to-treat rheumatoid arthritis
This trial combines traditional Chinese herbal medicine with standard Western treatments for people with rheumatoid arthritis that hasn't responded well to at least two prior medications. It aims to see if the combination is more effective and safe.
ShanghaiAges 18–70 - NCT07719140RecruitingPhase 4
Lower steroid dose study for children with lupus nephritis
This trial tests whether a lower starting dose of steroids can control kidney inflammation in children with lupus nephritis. It aims to reduce side effects while still treating the disease effectively.
Beijing, Beijing MunicipalityAges 6–18 - NCT07429721RecruitingEarly Phase 1
Testing QI-019A for multiple myeloma that came back
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
Wuhan, HubeiAges 18 years+ - NCT07494565RecruitingPhase 2
Celecoxib plus standard chemo for CD5+ DLBCL
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Guangzhou, GuangdongAges 18–80 - NCT07719556RecruitingPhase 2
Orelabrutinib with obinutuzumab and venetoclax for untreated MCL
This trial tests a new combination of three targeted drugs (orelabrutinib, obinutuzumab, and venetoclax) for people with newly diagnosed mantle cell lymphoma who have not had treatment before. The goal is to see if this short-course combination can effectively control the disease while being gentle on the body.
Changzhou, JiangsuAges 18 years+ - NCT07236502Recruiting
Moving forward with myeloma: Exercise and lifestyle program
This study tests a lifestyle program with exercise and nutrition guidance for people who have had multiple myeloma for at least one year. The goal is to see if it helps improve daily wellbeing and strength.
Maywood, IllinoisAges 18 years+ - NCT07720310Enrolling by invitation
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
Lyasny, Minsk OblastAges 18–70 - NCT07712939RecruitingPhase 1
Study of CND319 for rheumatic diseases
This study tests a new drug called CND319 in healthy volunteers and people with rheumatoid arthritis or Sjögren's disease. The goal is to see if it is safe and how the body responds to it.
Melbourne, VictoriaAges 18–65 - NCT07069699RecruitingPhase 1/Phase 2
Testing a new drug for lymphoma with MYC gene changes
This trial tests the safety of a new drug, CX-5461 (Pidnarulex), in people with certain types of aggressive B-cell lymphoma that have specific MYC gene changes. It aims to find out if this drug can help when standard treatments are no longer working.
Irvine, CaliforniaAges 18 years+ - NCT03889743RecruitingPhase 4
Steroid treatment to help prevent asthma after a first wheezing illness
This trial studies whether an early steroid treatment can lower the chance that children will go on to develop asthma after their first severe “wheezing” episode caused by a rhinovirus (a common cold virus). If you qualify, the goal is to prevent future asthma rather than just treat the current episode.
TurkuAges 3 months–1.9 years - NCT07076043RecruitingPhase 4
HIV prevention for young women getting reproductive health care
This study offers different forms of HIV prevention medicine (PrEP) to young women ages 18–30 who are visiting clinics for reproductive health services like family planning or postnatal care. It aims to see which delivery method works best for you.
Thika, Kiambu CountyAges 18–30 - NCT06260956Recruiting
Peanut and egg study for expecting mothers
This study looks at whether eating or avoiding peanuts and eggs during pregnancy can affect the baby's risk of allergies. You and your baby will be followed for a year after birth.
Rochester, New YorkAges 1 day+ - NCT06927999RecruitingPhase 2
Experimental medicine for chronic hives
This trial tests an experimental medicine for chronic hives (called chronic spontaneous urticaria). It is for people whose hives still bother them about once or twice a month despite daily treatment, and who do not have heart problems.
Glenview, IllinoisAges 18–65 - NCT04925375RecruitingPhase 2
Abatacept for children with CVID and lung scarring
This Phase 2 trial tests abatacept to improve a specific type of lung disease in children with common variable immunodeficiency (CVID). It aims to slow or reduce ongoing lung changes seen on CT scans while they continue their usual immune “replacement” therapy.
San Francisco, CaliforniaAges 4 years+ - NCT05861050RecruitingPhase 1/Phase 2
Study of 4-drug treatment for newly diagnosed high-risk mantle cell lymphoma
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
Duarte, CaliforniaAges 18–80 - NCT07094048RecruitingPhase 4
Immunoglobulins for multiple myeloma patients on BCMA T-cell engagers
This trial tests whether giving immunoglobulins (a treatment to boost your immune system) helps multiple myeloma patients who are receiving a BCMA-directed T-cell engager therapy. It aims to see if this can reduce infections and improve outcomes.
Lévis, QuebecAges 18 years+ - NCT07549698RecruitingPhase 1/Phase 2
CRISPR Gene Therapy for Immune Blood Disorders
This trial tests CTX112, a new CRISPR gene therapy that modifies your immune cells to treat severe immune thrombocytopenic purpura (ITP) or warm autoimmune hemolytic anemia (WAIHA) that hasn't responded to standard treatments. The goal is to see if it's safe and can help your body stop attacking its own blood cells.
Rochester, MinnesotaAges 18 years+ - NCT06564389RecruitingPhase 1
First-in-human study of PF-07832837 in healthy adults and eczema patients
This trial is testing a new investigational medicine (PF-07832837) for safety in healthy adults and in people with moderate to severe atopic dermatitis (eczema). It is a first-in-human study, so it looks at how well the body tolerates the medicine.
Anaheim, CaliforniaAges 18–70 - NCT07582133RecruitingPhase 2
Long-term safety study of HRS-5965 for IgA kidney disease
This study follows up on patients who participated in a previous trial (HRS-5965-305) testing a drug called HRS-5965 for IgA nephropathy, a kidney disease where the immune system damages the kidneys. Researchers want to check if the drug continues to be safe and well-tolerated over a longer period.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06967701Recruiting
Building exercise habits for type 1 diabetes
This study helps adults with type 1 diabetes who don't exercise much build a safe and lasting exercise routine. You'll learn how to start moving more while managing your insulin and blood sugar levels.
New Haven, ConnecticutAges 30–65
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,227 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,696 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.